The Trump administration's April 23 order reclassifying state-licensed medical cannabis as a Schedule 3 controlled substance does something no congressional vote has managed in decades: it removes the legal basis for applying Internal Revenue Code 280E to qualifying cannabis businesses. For multistate operators carrying hundreds of millions in deferred tax liability, that is not a minor policy footnote. It is a potential lifeline - or a prolonged exercise in uncertainty, depending entirely on what the U.S. Treasury Department decides to do next.
What the Rescheduling Order Actually Changes - and What It Doesn't
The order is direct on one point: state-licensed medical cannabis operators "will no longer be subject to the deduction disallowance imposed by Section 280E." That means businesses operating under a state medical marijuana license can - in principle - begin deducting ordinary business expenses the way any other legal retailer would. Rent, payroll, cost of goods, utilities. Expenses that Schedule 1 status had made untouchable for years.
Here's the catch, though. The same order contains a line that should give every cannabis CFO and tax attorney pause: "Nothing in this rule constitutes a determination regarding federal tax liability, and qualifying state licensees should consult with tax counsel regarding the applicability of Section 280E to their specific circumstances." In other words, the rescheduling clears the statutory path - but it doesn't tell you how to walk it.
Relief is already retroactive, but only back to January 2026, and only for medical cannabis operators. What happens before that date is unsettled. The order encourages the Treasury "to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license." Encourage. Consider. Neither word carries the weight of a binding directive.
The $1.6 Billion Question Nobody Has Answered
Publicly traded marijuana multistate operators - the MSOs - collectively owe the IRS an estimated $1.6 billion in 280E-related tax debt. The broader cannabis industry may have paid close to $15 billion in 280E taxes since 2018. Whether any of that money comes back, or whether past-due bills get reduced, hinges on a Treasury guidance document that had not been released as of late April.
What the Treasury has signaled, carefully, is that 280E "applies in years when cannabis was Schedule 1." That framing suggests the agency's default posture leans toward limiting relief to the period after rescheduling takes effect - not reaching back through prior tax years. The Treasury also indicated that guidance would address how businesses with both medical and adult-use operations can apportion expenses, which is a real operational problem for any MSO with licenses across multiple regulatory structures.
Adult-use operations, to be clear, are not covered by the current rescheduling order. Hearings addressing that question are set to begin June 29. Until those proceedings resolve, a dispensary licensed in a medical-only state and a dispensary licensed in an adult-use state are operating under different federal tax rules - even if they share the same corporate parent, the same point-of-sale system, and the same wholesale supply chain.
Operators Caught Between Medical and Adult-Use Markets
That dual-market reality is where things get operationally complicated. Consider a large MSO with medical licenses in Florida and Pennsylvania alongside adult-use licenses in New York and Maryland. How does it draw the 280E line? Which revenue streams are now deductible, and which remain subject to the old disallowance rules? The Treasury's forthcoming guidance on expense apportionment will matter enormously here - and the lack of that guidance right now creates genuine compliance risk.
The National Cannabis Industry Association has staked out a clear position: since 280E was never written with state-legal operators in mind, it should not apply to any tax year, for any license type. The NCIA published a white paper making that argument in detail. It's a reasonable policy position. Whether the Treasury shares it is another matter entirely, and the agency has not given any indication it will move that far.
What seems nearly certain, regardless of where Treasury lands, is that the question will end up in U.S. Tax Court. The retroactivity issue - how far back relief extends, and for which operators - is the kind of ambiguity that generates litigation. An operator facing a seven-figure past-due tax bill has every incentive to argue its case before a judge if Treasury guidance leaves the door cracked.
What Operators Should Be Doing Now
Waiting on Treasury guidance before taking any action is understandable. Acting without it is risky. The practical posture for most licensed cannabis businesses right now sits somewhere between those two poles.
- Medical-only operators should be working with tax counsel to document their license status, revenue allocation, and expense records for tax years where retroactive relief might eventually apply.
- MSOs with mixed medical and adult-use footprints should begin the internal accounting work needed to apportion expenses by license type - that segmentation will be required under any likely Treasury framework.
- Operators carrying significant past-due 280E liability should model multiple scenarios: full retroactive relief, partial relief, and no retroactive relief. The range of outcomes is still that wide.
- Businesses with open IRS audits or active tax disputes should consult counsel immediately about whether those proceedings are affected by the rescheduling order.
The rescheduling order is a genuine shift - arguably the most consequential federal action affecting cannabis business economics in years. But it is not a tax ruling. The Treasury still has to do that work, and until it does, the $15 billion question remains exactly that.
